1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention
    Journal Article

    Holtzman, N. G.; Curtis, L. M.; Salit, R. B.; Shaffer, B. C.; Pirsl, F.; Ostojic, A.; Steinberg, S. M.; Schulz, E.; Wilder, J. S.; Hughes, T. E.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
    Research Letter

    Hultcrantz, M.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; Lahoud, O. B.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Donor types and outcomes of transplantation in myelofibrosis: A CIBMTR study
    Journal Article

    Jain, T.; Estrada-Merly, N.; Salas, M. Q.; Kim, S.; DeVos, J.; Chen, M.; Fang, X.; Kumar, R.; Andrade-Campos, M.; Elmariah, H.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Population-based screening cohort study reveals no association between monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), multiple myeloma (MM), and alopecia
    Research Letter

    Sharma, D.; Ungar, B.; Adalsteinsson, J. A.; Sigurdsson, J. K.; Sharp, K.; Thorsteinsdóttir, S.; Rögnvaldsson, S.; Þórðardóttir, Á R.; Viðarsson, B.; Önundarson, P. T.; more...
    Archives of Dermatological Research (2024)

    Fulltext@MSK | Save
  • Efficacy and clinicogenomic biomarkers of response to dual versus single agent checkpoint inhibitor therapy in untreated metastatic non-small cell lung cancer
    Meeting Abstract

    Boiarsky, D.; Hong, L.; Ricciuti, B.; Cooper, A. J.; Saad, M. B.; Elkrief, A.; Di Federico, A.; Aminu, M.; Rinsurongkawong, W.; Lewis, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis
    Meeting Abstract

    Rampal, R.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Seven-year overall survival analysis from ECHELON-1 study of A+ AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma
    Meeting Abstract

    Ansell, S. M.; Straus, D. J.; Connors, J. M.; Jurczak, W.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J. W.; Advani, R. H.; Hutchings, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3
    Meeting Abstract

    Oluwole, O. O.; Ghobadi, A.; Cassaday, R. D.; Park, J. H.; Houot, R.; Logan, A.; Boissel, N.; Leguay, T.; Bishop, M. R.; Topp, M. S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma
    Meeting Abstract

    Pal, S. K.; Tannir, N. M.; Grell, P.; Gao, X.; Kotecha, R. R.; Picus, J.; De Braud, F. G.; Takahashi, S.; Wong, A.; Suarez, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Valdes, C. R.; Voorhees, P. M.; D'Souza, A.; Chung, A.; Tuchman, S.; Safah, H.; McKay, J. T.; Weisel, K. C.; Teipel, R.; Korde, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save